As previously reported, in this international study of nearly 2500 men who have sex with men (plus a small number of transgender women), daily
Truvada reduced the risk of HIV infection by 92% among participants
with blood drug levels indicating consistent use.
Truvada is a coformulation containing two drugs, tenofovir and emtricitabine, both of which are active against HBV as well as HIV.